Clinical and molecular basis of hepatocerebral mitochondrial DNA depletion syndrome in Japan: evaluation of outcomes after liver transplantation
Open Access
- 24 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 15 (1), 1-9
- https://doi.org/10.1186/s13023-020-01441-5
Abstract
Hepatocerebral mitochondrial DNA depletion syndrome (MTDPS) is a disease caused by defects in mitochondrial DNA maintenance and leads to liver failure and neurological complications during infancy. Liver transplantation (LT) remains controversial due to poor outcomes associated with extrahepatic symptoms. The purposes of this study were to clarify the current clinical and molecular features of hepatocerebral MTDPS and to evaluate the outcomes of LT in MTDPS patients in Japan. We retrospectively assessed the clinical and genetic findings, as well as the clinical courses, of 23 hepatocerebral MTDPS patients from a pool of 999 patients who were diagnosed with mitochondrial diseases between 2007 and 2019. Causative genes were identified in 18 of 23 patients: MPV17 (n = 13), DGUOK (n = 3), POLG (n = 1), and MICOS13 (n = 1). Eight MPV17-deficient patients harbored c.451dupC and all three DGUOK-deficient patients harbored c.143-307_170del335. The most common initial manifestation was failure to thrive (n = 13, 56.5%). The most frequent liver symptom was cholestasis (n = 21, 91.3%). LT was performed on 12 patients, including nine MPV17-deficient and two DGUOK-deficient patients. Among the 12 transplanted patients, five, including one with mild intellectual disability, survived; while seven who had remarkable neurological symptoms before LT died. Five of the MPV17-deficient survivors had either c.149G > A or c.293C > T. MPV17 was the most common genetic cause of hepatocerebral MTDPS. The outcome of LT for MTDPS was not favorable, as previously reported, however, patients harboring MPV17 mutations associated with mild phenotypes such as c.149G > A or c.293C > T, and exhibiting no marked neurologic manifestations before LT, had a better prognosis after LT.Keywords
Other Versions
Funding Information
- Japan Agency for Medical Research and Development (19ek0109273, 18ek0109177, 20ek0109468)
- Ministry of Education, Culture, Sports, Science and Technology
- Takeda Science Foundation
This publication has 33 references indexed in Scilit:
- Two patients with hepatic mtDNA depletion syndromes and marked elevations of S-adenosylmethionine and methionineMolecular Genetics and Metabolism, 2012
- MPV17-associated hepatocerebral mitochondrial DNA depletion syndrome: New patients and novel mutationsMolecular Genetics and Metabolism, 2010
- Fluctuating liver functions in siblings with MPV17 mutations and possible improvement associated with dietary and pharmaceutical treatments targeting respiratory chain complex IIMolecular Genetics and Metabolism, 2009
- Glucose metabolism and diet-based prevention of liver dysfunction in MPV17 mutant patientsJournal of Hepatology, 2009
- Clinical and molecular features of mitochondrial DNA depletion syndromesJournal of Inherited Metabolic Disease, 2008
- Lethal hepatopathy and leukodystrophy caused by a novel mutation in MPV17 gene: Description of an alternative MPV17 spliced formMolecular Genetics and Metabolism, 2008
- Mutations in theMPV17 gene are responsible for rapidly progressive liver failure in infancyJournal of Hepatology, 2007
- Biochemical Assays of Respiratory Chain Complex ActivityMethods in Cell Biology, 2007
- Navajo Neurohepatopathy Is Caused by a Mutation in the MPV17 GeneAmerican Journal of Human Genetics, 2006
- Diagnostic criteria for respiratory chain disorders in adults and childrenNeurology, 2002